EP1905761A1 — An improved process for the preparation of 4-[2-(methyl-2-pyridinylamino) ethoxy] benzaldehyde, an intermediate for the preparation of rosiglitazone
Assigned to Cadila Pharmaceuticals Ltd · Expires 2008-04-02 · 18y expired
What this patent protects
The invention relates to an improved process for the preparation of 4-[2-(methyl-2-pyridinylamino)ethoxy]-benzaldehyde via 4-[2-(methyl-2-pyridinylamino).ethoxy]-benzonitrile. The process of preparation of 4-[2-(methyl-2-pyridinylamino)ethoxy]-benzaldehyde comprises: (a) R…
USPTO Abstract
The invention relates to an improved process for the preparation of 4-[2-(methyl-2-pyridinylamino)ethoxy]-benzaldehyde via 4-[2-(methyl-2-pyridinylamino).ethoxy]-benzonitrile. The process of preparation of 4-[2-(methyl-2-pyridinylamino)ethoxy]-benzaldehyde comprises: (a) Reacting 2[methyl(pyridine-2-yl)amino]ethanol with 4-halobenzonitrile using a base in a solvent, to give 4-(2-[methyl(pyridine-2-yl)amino]ethoxy)benzonitrile, (b) reacting a solution of 4-(2-[methyl(pyridine-2-yl)amino]ethoxy)benzonitrile in formic acid with Raney nickel in water ,to give 4-[2-(methyl-2-pyridinylamino)ethoxy]-benzaldehyde.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.